Cationic polymer synergizing with chemotherapeutics and re-purposing antibiotics against cancer cells

Zheng, Yiran; Kng, Jessica; Yang, Chuan; Hedrick, James L.; Yang, Yi Yan

doi:10.1039/d0bm02155e

Cited by 7 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 A). When combined with only 20 μg mL −1 of oncolytic polymer, the IC 50 of doxorubicin for MCF-7 cells would be decreased from about 320 ng mL −1 to 0.5 ng mL −1 , suggesting a significant synergistic efficiency [ 199 ]. Due to the oncolytic polymer-mediated damage of the plasma membrane, the cellular uptake of doxorubicin into MCF-7 cells was observed to be increased by 2.5 ± 0.5 times after incubation for 2 h. In addition, the polymers also showed synergistic or additive effects with doxorubicin/paclitaxel/ciprofloxacin against MCF-7 cells, HepG2 cells, and MCF-7 ADR drug resistant cells, respectively.…”

Section: Advance Of Oncolytic Polymersmentioning

confidence: 99%

“…Reproduced by permission from Ref. [ 199 ] Copyright 2021 Royal Society of Chemistry. (B) a) The structure and synthesis process of aHLP-PDA nanoparticle, and the schematic diagram of its redox/heat dual-responsive behavior; b) Live/dead (Calcein-AM/PI) staining of the HeLa-TR cells incubated with aHLP-PDA nanoparticle at pH 7.4 or pH 6.8 after 5 min irradiation with a NIR laser at 1 W/cm 2 , scale bar = 50 μm; c) The tumor volume and survival rate after different treatments evaluated in the 4T1-R tumor-bearing BALB/c mice model.…”

Section: Advance Of Oncolytic Polymersmentioning

confidence: 99%

See 1 more Smart Citation

From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy

Liu

Shen

Liu

et al. 2024

Bioactive Materials

View full text Add to dashboard Cite

Section: Advance Of Oncolytic Polymersmentioning

confidence: 99%

Section: Advance Of Oncolytic Polymersmentioning

confidence: 99%

From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy

Liu

Shen

Liu

et al. 2024

Bioactive Materials

View full text Add to dashboard Cite

“…Triple-negative breast cancer [13] Acid-activatable membrane disruption of both stromal and cancerous cells Random copolymers of hexylmethacrylate, dimethyl aminoethylmethacrylate, and methacrylic acid Not available Pancreatic cancer [98] Membrane disruption and enhanced cellular uptake of chemotherapeutics, antibiotics and the polymer Quaternary ammonium-functionalized cationic polycarbonate Not available Liver cancer and drug-resistant breast cancer [128] P-gp inhibition and increased plasma membrane fluidity pH-sensitive polymeric micelles based on poly(2-ethyl-2-oxazoline)-poly(D,L-lactide)…”

Section: Not Availablementioning

confidence: 99%

Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics

Fei¹,

Yan²,

Wu³

et al. 2023

Theranostics

View full text Add to dashboard Cite

Cancer is generally considered a result of genetic mutations that cause epigenetic changes, leading to anomalous cellular behavior. Since 1970s, an increasing understanding of the plasma membrane and specifically the lipid alterations in tumor cells have provided novel insights for cancer therapy. Moreover, the advances in nanotechnology offer a potential opportunity to target the tumor plasma membrane while minimizing side effects on normal cells. To further develop membrane lipid perturbing tumor therapy, the first section of this review demonstrates the association between plasma membrane physicochemical properties and tumor signaling, metastasis, and drug resistance. The second section highlights existing nanotherapeutic strategies for membrane disruption, including lipid peroxide accumulation, cholesterol regulation, membrane structure disruption, lipid raft immobilization, and energy-mediated plasma membrane perturbation. Finally, the third section evaluates the prospects and challenges of plasma membrane lipid perturbing therapy as a therapeutic strategy for cancers. The reviewed membrane lipid perturbing tumor therapy strategies are expected to bring about necessary changes in tumor therapy in the coming decades.

show abstract

Silver ciprofloxacin (CIPAG): a multitargeted metallodrug in the development of breast cancer therapy

Banti,

Kalousi,

Psarra

et al. 2024

J Biol Inorg Chem

View full text Add to dashboard Cite

The anti-proliferative activity of the known metalloantibiotic {[Ag(CIPH)2]NO3∙0.75MeOH∙1.2H2O} (CIPAG) (CIPH = ciprofloxacin) against the human breast adenocarcinoma cancer cells MCF-7 (hormone dependent (HD)) and MDA-MB-231 (hormone independent (HI)) is evaluated. The in vitro toxicity and genotoxicity of the metalloantibiotic were estimated toward fetal lung fibroblast (MRC-5) cells. The molecular mechanism of the CIPAG activity against MCF-7 cells was clarified by the (i) cell morphology, (ii) cell cycle arrest, (iii) mitochondrial membrane permeabilization, and (iv) by the assessment of the possible differential effect of CIPAG on estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) transcriptional activation, applying luciferase reporter gene assay. Moreover, the ex vivo mechanism of CIPAG was clarified by its binding affinity toward calf thymus (CT-DNA). Graphical abstract

show abstract

Cationic polymer synergizing with chemotherapeutics and re-purposing antibiotics against cancer cells

Abstract: A quaternary ammonium-functionalized cationic polymer synergizes with existing chemotherapeutics and re-purposes antibiotics to increase therapeutic efficacy, mitigate toxicity and circumvent drug resistance via its membrane disruption mechanism.

Cited by 7 publications

References 47 publications

From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy

From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy

Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics

Silver ciprofloxacin (CIPAG): a multitargeted metallodrug in the development of breast cancer therapy

Contact Info

Product

Resources

About